Beirut: The American University of Beirut Medical Center (AUBMC) has successfully launched its Chimeric Antigen Receptor (CAR)-T Cell Therapy Program, marking a significant advancement in personalized cancer treatment in Lebanon. This breakthrough comes as the institution successfully treated its first patient with chemotherapy-resistant lymphoma, underscoring AUBMC's commitment to innovative cancer care.
According to National News Agency - Lebanon, the CAR-T Cell Therapy Program at AUBMC involves the local production of CAR-T cells, which are then subjected to a quality check before being infused into the patient. This process culminates with the confirmation of tumor response, indicating a successful treatment. AUBMC President Fadlo R. Khuri emphasized the transformative nature of this achievement, highlighting the university's dedication to excellence and impactful specialization.
CAR-T cell therapy is a leading-edge treatment that reprograms a patient's immune cells to target and destroy cancer cells, providing new hope for those with relapsed or treatment-resistant blood cancers. The establishment of this program is the result of years of extensive research, clinical expertise, and multidisciplinary collaboration, representing a significant milestone for AUBMC.
Dr. Ali Bazarbachi, director of the Bone Marrow Transplantation Program at AUBMC, expressed his pride in the program's success. He remarked on the importance of teamwork in achieving the goal of curing patients with blood cancers, likening the collaborative effort to an orchestra performing a piece of music.
The introduction of this potentially curative and life-saving therapy is a source of excitement for AUBMC, as it aims to offer new hope to patients in Lebanon and the wider region. The program not only signifies scientific innovation but also pioneers healthcare by redefining what is possible in the treatment of blood cancer.